Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Ruxolitinib in clinical practice for therapy of myelofibrosis: Single USA center experience following Food and Drug Administration approval2013 · 23 citations
2. 2Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients2000 · 279 citations
3. 3Response to ruxolitinib in patients with intermediate‐1–, intermediate‐2–, and high‐risk myelofibrosis: results of the UK ROBUST Trial2015 · 102 citations
4. 4Ruxolitinib for the treatment of primary myelofibrosis2014 · 14 citations
5. 5Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study2012 · 224 citations